Status:
COMPLETED
High Flow in Interstitial Lung Disease
Lead Sponsor:
Aalborg University Hospital
Collaborating Sponsors:
Fisher and Paykel Healthcare
Conditions:
Lung Diseases, Interstitial
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, 6 week cross-over study on the effect of High flow nasal cannula (HFNC) delivered air in patients with interstitial lung disease (ILD), in need of ambulatory oxygen therapy. Pr...
Detailed Description
In this pilot study we wish to investigate whether treatment with HFNC, delivered by MyAirvo2 (Fisher\&Paykel, Auckland, New Zealand) in patients with interstitial lung disease (ILD) in need of ambula...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Age \> 18 years old
- Patient diagnosed with interstitial lung disease
- Capable of understanding oral and written information and giving informed consent
- Newly diagnosed with need of oxygen during physical activity (SO2 \<88%).
- Exclusion criteria
- Pneumonia or exacerbation of ILD \< 6 weeks prior to inclusion
- Other terminal disease than ILD and life expectancy \< 3 months
- Patients not capable of understanding and accepting written or verbal information
- Patients with in need of continuous oxygen treatment at inclusion
Exclusion
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03816722
Start Date
February 15 2019
End Date
June 30 2021
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalborg University Hospital
Aalborg, Denmark, 9100